Evolent Health Statistics
Total Valuation
Evolent Health has a market cap or net worth of $1.00 billion. The enterprise value is $1.62 billion.
Important Dates
The next estimated earnings date is Thursday, August 7, 2025, after market close.
| Earnings Date | Aug 7, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Evolent Health has 115.86 million shares outstanding. The number of shares has increased by 1.89% in one year.
| Current Share Class | 115.86M |
| Shares Outstanding | 115.86M |
| Shares Change (YoY) | +1.89% |
| Shares Change (QoQ) | +0.25% |
| Owned by Insiders (%) | 1.38% |
| Owned by Institutions (%) | 101.53% |
| Float | 103.47M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 19.96 |
| PS Ratio | 0.41 |
| Forward PS | 0.46 |
| PB Ratio | 1.07 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | 54.34 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.68 |
| EV / EBITDA | 19.24 |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.98, with a Debt / Equity ratio of 0.77.
| Current Ratio | 0.98 |
| Quick Ratio | 0.92 |
| Debt / Equity | 0.77 |
| Debt / EBITDA | 9.45 |
| Debt / FCF | n/a |
| Interest Coverage | -0.06 |
Financial Efficiency
Return on equity (ROE) is -9.24% and return on invested capital (ROIC) is -0.06%.
| Return on Equity (ROE) | -9.24% |
| Return on Assets (ROA) | -0.04% |
| Return on Invested Capital (ROIC) | -0.06% |
| Return on Capital Employed (ROCE) | -0.09% |
| Revenue Per Employee | $533,053 |
| Profits Per Employee | -$31,218 |
| Employee Count | 4,500 |
| Asset Turnover | 0.91 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -508,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.58% in the last 52 weeks. The beta is 0.88, so Evolent Health's price volatility has been lower than the market average.
| Beta (5Y) | 0.88 |
| 52-Week Price Change | -63.58% |
| 50-Day Moving Average | 9.06 |
| 200-Day Moving Average | 14.88 |
| Relative Strength Index (RSI) | 51.22 |
| Average Volume (20 Days) | 1,854,324 |
Short Selling Information
The latest short interest is 16.72 million, so 14.43% of the outstanding shares have been sold short.
| Short Interest | 16.72M |
| Short Previous Month | 16.09M |
| Short % of Shares Out | 14.43% |
| Short % of Float | 16.16% |
| Short Ratio (days to cover) | 7.09 |
Income Statement
In the last 12 months, Evolent Health had revenue of $2.40 billion and -$140.48 million in losses. Loss per share was -$1.22.
| Revenue | 2.40B |
| Gross Profit | 365.72M |
| Operating Income | -1.79M |
| Pretax Income | -88.91M |
| Net Income | -140.48M |
| EBITDA | 84.43M |
| EBIT | -1.79M |
| Loss Per Share | -$1.22 |
Full Income StatementBalance Sheet
The company has $246.55 million in cash and $870.10 million in debt, giving a net cash position of -$623.55 million or -$5.38 per share.
| Cash & Cash Equivalents | 246.55M |
| Total Debt | 870.10M |
| Net Cash | -623.55M |
| Net Cash Per Share | -$5.38 |
| Equity (Book Value) | 1.13B |
| Book Value Per Share | 8.07 |
| Working Capital | -11.16M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $18.42 million and capital expenditures -$39.48 million, giving a free cash flow of -$21.06 million.
| Operating Cash Flow | 18.42M |
| Capital Expenditures | -39.48M |
| Free Cash Flow | -21.06M |
| FCF Per Share | -$0.18 |
Full Cash Flow StatementMargins
Gross margin is 15.25%, with operating and profit margins of -0.07% and -4.54%.
| Gross Margin | 15.25% |
| Operating Margin | -0.07% |
| Pretax Margin | -4.56% |
| Profit Margin | -4.54% |
| EBITDA Margin | 3.52% |
| EBIT Margin | -0.07% |
| FCF Margin | n/a |
Dividends & Yields
Evolent Health does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.89% |
| Shareholder Yield | -1.89% |
| Earnings Yield | -14.03% |
| FCF Yield | -2.10% |
Dividend DetailsAnalyst Forecast
The average price target for Evolent Health is $16.79, which is 94.33% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.79 |
| Price Target Difference | 94.33% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 14 |
| Revenue Growth Forecast (5Y) | 7.98% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Evolent Health has an Altman Z-Score of 1.35 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.35 |
| Piotroski F-Score | 3 |